

**Annual General Meeting of Shareholders
of
HLS THERAPEUTICS INC.
(the “Company”)**

**June 20, 2025
REPORT OF VOTING RESULTS**

Pursuant to Section 11.3 of
National Instrument 51-102 – *Continuous Disclosure Obligations* (“NI 51-102”)

In accordance with section 11.3 of NI 51-102 and following the annual general meeting of shareholders of the Company held on June 20, 2025 (the “**Meeting**”), we hereby advise of the following voting results as tabulated.

Total common shares issued and outstanding at record date (May 12, 2025)	31,634,357
Total shares represented at the Meeting in person and by proxy	16,073,335
Percentage of total shares represented at the Meeting	50.81%

Election of Directors

The election of directors was conducted by ballot. Each of the ten nominees in the Company’s management information circular dated May 13, 2025 was elected to serve until the end of the next annual meeting of shareholders or until his or her successor is duly elected or appointed. The percentage of votes cast “for” or “withheld” from the vote are set forth below opposite the name of each elected director based on proxies and votes received at the Meeting.

Name of Nominee	Votes Cast FOR	% of Vote Cast FOR	Votes WITHHELD	% of Votes WITHHELD
John Welborn	14,875,706	99.88	17,983	0.12
Craig Millian	14,875,670	99.88	18,019	0.12
John Hanna	14,875,706	99.88	17,983	0.12
Rodney Hill	14,867,448	99.82	26,241	0.18
Norma Beauchamp	12,166,114	81.69	2,727,575	18.3
Kyle Dempsey	13,939,086	93.59	954,603	6.41
Christian Roy	14,866,122	99.81	27,567	0.19
Christine Elliott	13,946,066	93.64	947,623	6.36

Re-Appointment of Auditor

An ordinary resolution to re-appoint Ernst & Young LLP to serve as the independent auditor of the Company and authorizing the directors of the Company to fix the auditor’s remuneration was approved by ballot. Based on proxies and votes received at the Meeting, 16,073,134 votes (100%) were cast “for” and 201 votes (0%) were withheld.